AML - FOI Response Register

1. Please complete the table below with how many newly diagnosed patients with AML have started first-line treatment with each of the following therapies during the 6-month period February 2024 to July 2024?

• Azacitidine monotherapy
• Low dose cytarabine (LoDAC) monotherapy
• Venetoclax + azacitidine
• Venetoclax + LoDAC
• Ivosidenib
• Intensive chemotherapy-based regimen

Examples include: cytarabine and daunorubicin, idarubicin, fludarabine, mitoxantrone, etoposide (VP-16), 6-thioguanine (6-TG), methotrexate (MTX) or 6-mercaptopurine (6-MP), gemtuzumab ozogamicin with daunorubicin cytarabine, or FLAG-Ida (fludarabine, cytarabine, granulocyte-colony stimulating factor and idarubicin)

• Best supportive care
• Other

Do not include prophylactic therapies such as GCSF, anti-fungals, antihistamines, anti-nauseants.

Note: this should only include patients with AML who have started first-line treatment during the 6-month window

Given the short time period, the specific health condition, the low numbers involved and the small population of Shetland, NHS Shetland considers that providing any responses, even <5 answers, carries a high risk of identifying individuals or disclosing sensitive information about individuals. As such and in accordance with FOISA s 16(1), NHS Shetland confirms that it holds the information requested but that it is exempt from disclosure under FOISA s 38(1)(b) as read with s 38 (2A) as the information constitutes personal data and disclosure would breach the confidentiality of the data subjects.